| Market Capitalization (Millions $) |
2,819 |
| Shares
Outstanding (Millions) |
111 |
| Employees |
1,784 |
| Revenues (TTM) (Millions $) |
453 |
| Net Income (TTM) (Millions $) |
-178 |
| Cash Flow (TTM) (Millions $) |
-106 |
| Capital Exp. (TTM) (Millions $) |
32 |
Business Description
Zai Lab Limited (ZLAB) is a Chinese biopharmaceutical company that focuses on discovering, developing, and commercializing innovative medicines for the treatment of oncology, autoimmune, and infectious diseases. The company was founded in 2014 by Dr. Samantha Du, an experienced pharmaceutical executive with a proven track record of successful drug development and commercialization.
Zai Lab has a broad pipeline of product candidates that target a range of diseases, including several late-stage clinical programs that are approaching commercialization. The company's lead product candidate is Zejula, a PARP inhibitor that is currently in Phase III clinical trials for the treatment of ovarian cancer. The company is also developing other oncology drugs, including novel kinase inhibitors and immuno-oncology therapies.
In addition to its oncology pipeline, Zai Lab has several product candidates in development for autoimmune diseases, such as atopic dermatitis and rheumatoid arthritis, as well as infectious diseases, such as COVID-19 and hepatitis B.
Zai Lab has a strong track record of partnership and collaboration with leading biopharmaceutical companies, including Sanofi, Bristol Myers Squibb, and GlaxoSmithKline. These partnerships have provided Zai Lab with access to key technologies and expertise, and have helped to accelerate the development of its product candidates.
The company aims to become a leading biopharmaceutical company in China, and has invested heavily in building a world-class research and development infrastructure. This includes state-of-the-art laboratories and manufacturing facilities, as well as a team of experienced scientists and researchers.
Zai Lab has a strong financial position, with a market capitalization of over $18 billion as of June 202 The company has a solid balance sheet, with over $1 billion in cash, cash equivalents, and short-term investments as of March 31, 202
In summary, Zai Lab Limited is a rapidly growing Chinese biopharmaceutical company with a portfolio of innovative product candidates in oncology, autoimmune diseases, and infectious diseases. The company has established strong partnerships with leading biopharmaceutical companies and has invested heavily in research and development infrastructure. With a strong financial position and a growing pipeline of product candidates, Zai Lab is well-positioned for continued success in the biopharmaceutical industry.
Company Address: 899 Halei Road Shanghai 201203
Company Phone Number: 6163 2588 Stock Exchange / Ticker: NASDAQ ZLAB
|
1.75% 
30.08 %